In the hoopla that followed the sequencing of the human genome in 2000, much of the excitement centered on the promise of miracle cures molecularly tailored to each individual.

FORBES: Good Genes

At this point, though, I can say that this should be a very positive step towards establishing beyond any doubt another therapeutic option for patients with GIST using a novel molecularly-targeted agent if Gleevec proves inadequate to control the disease.

FORBES: Pfizer Cancer Pill Proves Effective